Immune Regulation News

Immune Regulation News is an online resource covering research into the regulation, suppression, and modulation of the immune system.

Subscribe|Follow Us On

MCT1 Inhibition Reprograms Treg Metabolism via ABC Transporters: Implications for Tumor Immunity and the Prognosis of Acute Myeloid Leukemia Patients

March 13, 2026

[European Journal of Medical Research] Researchers investigated how monocarboxylate transporters (MCT) 1 inhibition modulates Treg metabolism and function, and the potential implications for tumor immunotherapy.

T-Bet Tissue-Resident Regulatory T Cells Are Enriched in the Neonatal Mouse Liver and Promoted by IL-27 and IFN-γ

March 13, 2026

[FEBS Journal] Scientists conducted single-cell transcriptomic and immunophenotypic analyses of liver- and spleen-derived Tregs from neonatal and adult mice.

Lyn Governs the Establishment and Maintenance of B Cell Anergy by Suppressing PI3K Signaling

March 13, 2026

[Nature Communications] The Src family kinase Lyn is known to be involved in the induction and maintenance of peripheral B cell tolerance. Scientists utilized a system in which Lyn deletion is tamoxifen inducible and B cell restricted, which allows acute elimination of Lyn in B cells only, minimizing confounding factors.

B Cells and Humoral Immunity in Melanoma: Regulatory and Autoimmune-Like Features and Implications for Immunotherapy

March 13, 2026

[Oncoimmunology] The authors underscore a dual role for B cells in melanoma, supporting antitumor immunity or promoting immune escape, and highlight opportunities to target regulatory B cells, correct isotype imbalance, and leverage B cell signatures as biomarkers.

Identification and Characterization of Dietary Antigens in Oral Tolerance

March 13, 2026

[Science Immunology] Researchers found that epitopes derived from seed storage proteins are targets of murine intestinal Treg cells, with the most frequent response targeting the C terminus of the maize protein alpha-zein.

Th17/Treg Cell Imbalance in Allergic Rhinitis: Mechanisms and Therapeutic Implications

March 13, 2026

[Genes and Immunity] Scientists provide a comprehensive analysis of the immune imbalance of allergic rhinitis, focusing on the key role of Th17/Treg cell imbalance in the pathogenesis of diseases.

The Different Meanings of Tolerating the Gut Microbiome

March 13, 2026

[Mbio] Using the intestinal mucosa as a paradigm, scientists explore how the gut microenvironment fosters the generation of tolerogenic antigen-presenting cells and microbe-specific Tregs to enforce immunological tolerance.

CAR T Cells Targeting CCR4 Selectively Deplete Human Tregs Ex Vivo and In Vivo

March 13, 2026

[Blood Advances] Scientists evaluated human-specific CCR4-directed CARTs previously developed for T cell malignancies and determined whether these CARTs could deplete human Tregs ex vivo and in vivo.

Immune Imbalance Between T Helper 1, T Helper 17, and Regulatory T Cells Fuels Amyotrophic Lateral Sclerosis Pathogenesis: Disease Trajectory, Diagnosis, and Therapeutic Implications

March 13, 2026

[Journal of Neuroinflammation] In amyotrophic lateral sclerosis, both Treg number and suppressive function decline, with remaining Tregs showing reduced FOXP3, the master transcription factor governing Treg function, expression and impaired regulatory capacity.

Sex Specific Effects of Adoptive Tregs Transfer on the Brain and Periphery in Maternal Immune Activation Offspring Rescuing Immune Dysregulation

March 13, 2026

[Journal of Neuroinflammation] Scientists investigated whether adoptive transfer of wildtype Tregs into maternal immune activation (MIA) offspring recipients could rescue immune activation, brain transcriptome changes, and behaviors exhibited in adult MIA offspring.

Citius Oncology Announces Positive Topline Results from Investigator‑Initiated Phase I Study of LYMPHIR™ in Combination with Pembrolizumab in Relapsed or Refractory Gynecologic Cancers

March 13, 2026

[Citius Oncology, Inc.] Citius Oncology, Inc. announced positive topline results from a completed investigator‑initiated Phase I clinical trial evaluating the direct Treg cell depletion activity of LYMPHIR™ in combination with the PD-1 immune checkpoint inhibitor pembrolizumab in patients with recurrent or refractory gynecologic cancers.

Pilatus Biosciences Announces First Patient Dosed in Phase I Trial of First-in-Class Metabolic Checkpoint Antibody PLT012 in Solid Tumors

March 13, 2026

[Pilatus Biosciences, Inc.] Pilatus Biosciences, Inc. announced the first patient has been dosed in its Phase I clinical trial evaluating PLT012, a first-in-class anti-CD36 monoclonal antibody for the treatment of advanced solid tumors.

For over a decade, Immune Regulation News has been keeping the scientific community up-to-date with the latest research and reviews related to immune regulation. Key research areas covered include the roles of regulatory T cells (Treg cells) in autoimmunity and self-reactivity, as well as immune response to disease, transplantation and cancer. We also provide vital updates on the latest jobs and upcoming events in the field of immunology.